Pneumococcal vaccination of older persons is thought to be cost-effective in preventing pneumococcal pneumonia, but evidence of clinical protection is uncertain. Because there is better evidence of vaccination effectiveness against invasive pneumococcal disease, we determined the cost-effectiveness of pneumococcal vaccination of persons aged у65 years in preventing hospital admission for both invasive pneumococcal disease and pneumococcal pneumonia in 5 western European countries. In the base case analyses, the cost-effectiveness ratios for preventing invasive disease varied from ∼11,000 to ∼33,000 European currency units (ecu) per quality-adjusted life year (QALY). Assuming a common incidence (50 cases per 100,000) and mortality rate (20%-40%) for invasive disease, the cost-effectiveness ratios were !12,000 ecu per QALY in all 5 countries. For preventing pneumococcal pneumonia, vaccinating all elderly persons would be highly cost-effective to cost saving. Public health authorities should consider policies for encouraging pneumococcal vaccination for all persons aged у65 years.
United Kingdom, Sweden, Belgium, Norway, Denmark, Finland, and Germany [16, 17] . Moreover, increases in vaccine use have also been observed in most of these countries. More rapid change in vaccination policies and increases in vaccine uptake might occur if additional evidence were to become available on its cost-effectiveness.
Several studies in western Europe have shown that pneumococcal vaccination of older persons would be cost-effective in preventing pneumococcal pneumonia [18] [19] [20] . Because there is limited evidence that vaccination is clinically effective in preventing all cases of pneumococcal pneumonia, nonbacteremic as well as bacteremic [21, 22] , and there is better evidence that it is effective in preventing invasive disease, information on the cost-effectiveness of vaccination in preventing invasive disease could provide strong support for public policies to vaccinate older persons. In the United States, pneumococcal vaccination of older persons has been shown to be highly cost-effective in preventing hospitalization for pneumococcal bacteremia, and in most instances, it is cost-saving [23] . Because of differences between the United States and countries in western Europe regarding the organization and costs of health care, these findings may not be persuasive to vaccination policy makers in western Europe. They may be more likely to accept cost-effectiveness studies if the studies reflect European experience, are multinational in scope, and consider the cost-effectiveness of vaccination in preventing invasive disease.
In this study, we examined the cost-effectiveness of pneumococcal vaccination in preventing invasive pneumococcal dis-ease because there is convincing evidence of its clinical effectiveness for this outcome. However, to compare our results with those of other studies, we also estimated the cost-effectiveness of vaccination in preventing pneumococcal pneumonia. Our study is one of few multinational cost-effectiveness studies of health care interventions [24] .
Methods
Model. In performing our economic evaluation, we followed the principles of "reference case analysis" [25] . We developed a cohort model and applied it to each of 5 countries: Belgium, France, Scotland, Spain, and Sweden. Two hypothetical cohorts of individuals aged у65 years were considered: 1 group who received pneumococcal vaccine and 1 group who did not receive pneumococcal vaccine. Both cohorts were followed up during the rest of their life spans. The life span of the cohort without vaccination was calculated on the basis of age-specific mortality rates (Eurostat, Luxembourg). Vaccination would influence the age-specific mortality rates during the period of vaccine efficacy. The model allowed us to calculate the consequences of vaccination for single years of each age group 165 years. The difference in life years between the 2 cohorts was calculated for each age group for each year of life. The life years gained due to vaccination were then corrected for quality of life and discounted, leading to the number of quality-adjusted life years (QALYs) gained.
The differences in hospitalization costs for invasive pneumococcal disease and pneumococcal pneumonia were calculated for the 2 cohorts. These costs were calculated for each age group and for each year of life as a function of hospital admission rate, average length of stay (ALOS), cost of 1 day of hospitalization, and vaccine efficacy. Finally, the cost per QALY gained as a result of vaccination was determined. All results were expressed as cost-effectiveness ratios (CERs; i.e., the costs of achieving 1 additional QALY in the vaccinated cohort).
We carried out our analyses by using a societal point of view. To reflect the time preference of society, we discounted all future costs and QALYs at 3% in the base case analyses [25] . Because other studies have demonstrated that the cost-effectiveness of pneumococcal vaccination varies considerably with age [20, 23] , we performed separate analyses for persons aged 65-74 years, 75-84 years, and у85 years, as well as for all persons aged у65 years. The base case analyses used the specific epidemiological and economic values for each variable in each country. We also performed sensitivity analyses for persons aged у65 years and varied the values of uncertain variables over their reasonable ranges. (A full description of the model is available on request.)
Health effects. To calculate QALYs, we incorporated data on the incidence and mortality rates of invasive pneumococcal disease and pneumococcal pneumonia, data on the effectiveness of pneumococcal vaccination, and data on age-specific mortality rates and age-specific differences in quality of life. Data on the effectiveness of pneumococcal vaccination were drawn from a case-control study of invasive disease that provides the only available information on vaccination effectiveness by age group and on declining protection over time [3] ; for example, the effectiveness for persons aged у65 years ranges from 75% in the first year to 33% in the sixth year after vaccination. These data were used in the US study on the cost-effectiveness of vaccination in preventing pneumococcal bacteremia [23] . We assumed the same effectiveness of vaccination in preventing pneumococcal pneumonia as in preventing invasive disease, an assumption supported by the results of earlier clinical trials in South Africa [17] . We further assumed that the vaccine covers 88% of capsular polysaccharide types causing invasive disease and pneumococcal pneumonia [23, 26] . We did not include adverse events following vaccination in our analyses, as the incidence of 5 cases of anaphylaxis per 1 million doses of vaccine administered, used in the earlier US study, had very little effect on the results [23] . In order to reflect less-than-perfect health during surviving years, we adjusted for quality of life by multiplying years of life gained by statistical weights published in the US National Health Interview Survey [27] [17, 28] . Numerous clinical studies have shown that definite pneumococcal pneumonia (i.e., positive blood culture) and probable pneumococcal pneumonia (variously defined but usually including purulent sputum with Gram staining and/or culture of sputum positive for Streptococcus pneumoniae) account for ∼30%-50% of all adult cases of community-acquired pneumonia that require hospitalization [17] . We used 40% as an estimate of incidence in our base case analyses.
For each country, information on the number of hospital discharges, ALOS, and mortality rates for pneumonia (ICD-9-CM 480-486; first-listed diagnosis) were obtained for each age group (table 1) . For Belgium, Spain, and Sweden, hospital data were obtained for 1995 from national registrations maintained by the Ministries of Health (see Appendix; B1, Sp1, and Sw1). For France, hospital data were obtained from 35 hospitals in the Rhô ne-Alpes region for 1995 (F1). For Scotland, hospital data were obtained from all nonobstetric, nonpsychiatric National Health Service hospital discharge records for 1995 (Sc1). Because the Scottish ALOS and mortality data included information from long-stay medical facilities and geriatric units, we truncated the ALOS and mortality data sets to exclude those cases with more than twice the median ALOS.
Invasive pneumococcal disease. All laboratory isolates of S. pneumoniae obtained from normally sterile extrapulmonary sites (e.g., blood, CSF, joint space, etc.) were considered as invasive isolates. When multiple isolates were obtained from the same patient during the same hospital stay, they were counted as a single case. Reports of invasive isolates also included data on ALOS and the outcome of hospital care (survived or died; table 1). In all countries, data on the incidence of invasive pneumococcal disease were obtained for 1 year from the clinical microbiology laboratories of hospitals that serve a population of a region (or a country) of at least 3 million persons. For smaller regions, a longer period was chosen to obtain a similar number of person years of observation. When complete reports from all clinical microbiology laboratories in a region were not available, reports were accepted as representative if they came from a subset of hospitals that accounted for 190% of all discharges of patients aged у65 years in the region. In Belgium, data on the incidence of invasive pneumococcal disease were obtained from 10 hospital laboratories in Flemish Brabant (1,100,000 inhabitants) for the period 1995-1997 (B2). Mortality and ALOS data for pneumonia were applied as a proxy for mortality and ALOS data for invasive pneumococcal disease because the latter were not available (B1). For France, data on the incidence of invasive pneumococcal disease were obtained from the National Network for Public Health for 1996. Mortality and ALOS data were based on information from a sample of 5 different hospitals in several regions for 1995-1997 (F2). For Scotland (5,100,000 inhabitants), data on the incidence of invasive disease (defined by blood and CSF isolates) were obtained from all National Health Service hospital bacteriology laboratories for 1995 (Sc2). ALOS and mortality data for pneumonia were applied as a proxy for ALOS and mortality data for invasive disease because the latter were not available (Sc1). For Spain, incidence and ALOS data on invasive disease were based on all hospital laboratory reports in the Valencian autonomous community (3,500,000 inhabitants) for 1995 (Sp2). Mortality data for pneumonia were applied as a proxy for mortality data for invasive disease because the latter were not available (Sp1). For Sweden, incidence, mortality, and ALOS data on invasive disease were obtained from a prospective study of community-acquired pneumococcal bacteremia treated in all hospitals in Stockholm County (1,600,000 inhabitants) for the 2-year period from 1 September 1993 to 31 August 1995 (Sw2).
Economic variables. Given differences in health care systems in the 5 countries, the approach to estimate costs varied from country to country. Wherever data were available, estimates were based on real costs (i.e., on resources consumed rather than on charges) [29] . Medical costs included the costs for purchasing and administering the vaccine and the hospital costs for the treatment of invasive pneumococcal disease or pneumococcal pneumonia (table  2) . Costs were estimated in each national currency and are presented in 1995 European currency units (ecu; table 2). (The ecu was replaced by the Euro in January 1998, which at that time had nearly the same value as the 1995 ecu.) For Belgium, France, Scotland, and Spain, all costs were standardized for 1995 by considering each country's medical price index, defined as the annual increase in medical prices during the period 1985-1995 (B3, F3, Sc3, and Sp3). These data were not available for Sweden; therefore, the general price increase was applied (Sw3).
The prices for pneumococcal vaccine in each country were retail prices (Aventis Pasteur MSD, unpublished data). Although the study was based on 1995 epidemiological and economic data, vaccine prices for 1998 were used. Two approaches were used to estimate the costs of administering pneumococcal vaccine. The base case analyses considered the cost saving from simultaneous pneumococcal and influenza vaccination. Four of the study countries recommend annual influenza vaccination for all elderly persons: France (persons aged у70 years), Spain and Sweden (persons aged у65 years), and Belgium (persons aged у60 years). In Scotland, influenza vaccination was recommended only for persons with high-risk medical conditions in 1995, but routine vaccination of persons aged у75 years was introduced in 1998. Pneumococcal and influenza vaccines can be administered concurrently at separate sites without adverse effects and without compromising their immunogenicity [16, 30] , and most doses of pneumococcal vaccine are administered during the influenza vaccination season each year (D. S. Fedson, unpublished observation). In Spain and the Netherlands, adding pneumococcal vaccination to an influenza vaccination program incurs extra administrative costs of 2.59 ecu [31] and 4.02 ecu, respectively (M. Postma, unpublished observation). In our base case analyses, we used 3.00 ecu for all 5 countries. The sensitivity analyses considered the costs of administering pneumococcal vaccine by itself. Estimates of these costs varied between countries (table 2). In Belgium, France, Scotland, and Sweden, the vaccine is administered by general practitioners (GPs). In Belgium and France, these costs were estimated by the fees that GPs receive for each consultation for vaccination (B4 and F4). For Scotland and Sweden, they were based on real cost estimates for GP consultations, and in the case of Sweden, they were corrected for the number of vaccinations that can be carried out during one consultation (Sc4 and Sw4). In Spain, GP costs were estimated by dividing the total national GP costs by the total national number of GP consultations for 1995 (Sp4).
The costs of treating invasive pneumococcal disease and pneumococcal pneumonia were limited to the costs associated with hospitalization. Because reimbursement systems differ among the 5 countries, it was not possible to develop a uniform approach to estimate costs for each hospital stay. In countries where hospital care is financed according to diagnosis-related groups (DRGs), DRG reimbursements were considered to be the best basis for estimating the costs of hospital care. To reflect age-specific hospital care costs, these costs were divided by the ALOS for each specific age group to arrive at daily hospital care costs. This approach was used for Spain (DRGs 079, 080, 089, 090, 091, and 489) and Sweden (DRGs 089 and 090) for 1995 (Sp5 and Sw5). The approach was also applied for France (DRG 129), although DRGs are not used for hospital financing in this country (F5). In Belgium and Scotland, where hospital care is financed through global budgets, the costs of each episode were estimated by multiplying the ALOS by the average cost per day. For Belgium, these estimates were based on an evaluation of 410 detailed invoices for the care of patients with pneumonia in 46 general and 4 university hospitals in 1995 (B5). For Scotland, the daily hospital costs were estimated by dividing total national hospital costs by the total national number of hospital days for 1995 (Sc5). Estimates of hospital care costs included only costs related to acute care: costs of long-term care and psychiatric care were excluded. Medication costs, specialist salaries, and hospital overhead and investment costs were included in the costs of hospital care. All costs of outpatient care were excluded.
Results

Base case analyses.
To prevent invasive pneumococcal disease in persons aged у65 years, CERs varied from ∼11,000 ecu per QALY for Spain to ∼33,000 ecu per QALY for Sweden (table 3) . If vaccination is also clinically effective in preventing pneumococcal pneumonia, vaccination was highly cost-effective to cost saving in all 5 countries (table 3). The age-specific results showed no clear pattern of increasing or decreasing costeffectiveness. Increases in incidence, mortality rates, and hospital resource use in older age groups appeared to cancel out declining vaccination effectiveness observed with increasing age.
Sensitivity analyses. We conducted univariate sensitivity analyses for all persons aged у65 years for invasive pneumococcal disease (table 4) . When pneumococcal vaccine was administered by itself and not with influenza vaccine, CERs increased in some countries as much as 2-fold. When alternative values for the incidence of disease were assumed (e.g., 50 cases of invasive pneumococcal disease per 100,000 elderly persons), CERs decreased in 4 countries (∼8000 ecu per QALY for France and Scotland and ∼16,000 ecu per QALY for Belgium and Sweden) but not in Spain (∼13,000 ecu per QALY). When the mortality rate of invasive disease for all persons aged у65 years was assumed to be 40%, CERs decreased considerably and varied from ∼4000 ecu per QALY for Spain to ∼12,000 ecu per QALY for Scotland. Alternative assumptions on vaccine prices, vaccination effectiveness, not applying the quality-of-life adjustment, and the discount rate had relatively large impacts on the results. For example, when cost and benefits were not discounted, CERs varied from ∼7000 ecu per QALY (for Spain) to ∼24,000 ecu per QALY (for Sweden). NOTE. Data are cost-effectiveness ratios in European currency units (1995) per quality-adjusted life year gained for persons aged у65 years. See text for details. In the 2-way SA, only incidence and mortality data were changed. All other values were the same as those used in the base case analyses.
a Incidence was 50 cases per 100,000 persons aged у65 years.
Because epidemiological data on the incidence and mortality rate of invasive disease differed substantially among the 5 countries (table 1) , we also conducted a 2-way sensitivity analysis for each country. We assumed a common incidence of invasive pneumococcal disease of 50 cases per 100,000 persons aged у65 years and varied mortality rates from 20% to 40%; all other variables were those used in the base case analyses. In all countries, approximate CERs were as follows: !12,000 ecu per QALY for a mortality rate of 20%, !8000 ecu per QALY for a rate of 30%, and !6000 ecu per QALY for a rate of 40% (table 5) .
Discussion
The cost-effectiveness of pneumococcal vaccination varied considerably across the 5 countries. When vaccination against invasive disease alone was considered, CERs in the base case analyses ranged from ∼11,000 to ∼33,000 ecu per QALY. Policy makers generally consider interventions with CERs !$20,000 (about 20,000 Euro in December 1999) per QALY as acceptably cost-effective, while CERs from $20,000 to $100,000 per QALY are considered moderately cost-effective [32] . Therefore, our findings, which are based on country-specific data, indicate that pneumococcal vaccination to prevent invasive pneumococcal disease alone can be considered an acceptably to moderately cost-effective intervention in all 5 countries.
In our analyses, pneumococcal vaccination to prevent pneumococcal pneumonia in older persons was highly cost-effective to cost saving in all countries. Although pneumococcal vaccination clearly prevents bacteremic pneumococcal pneumonia in older persons, whether it prevents all cases of pneumococcal pneumonia (nonbacteremic as well as bacteremic) has been a topic of considerable dispute [6, 11, 13, 14, 17, 21, 22, 33, 34] . A recent report indicates that pneumococcal vaccination reduces rates of hospitalization for pneumonia and all-cause mortality rates among persons with chronic lung disease [35] . Nonetheless, we believe that our findings on the cost-effectiveness of pneumococcal vaccination in preventing pneumococcal pneumonia should be interpreted with caution.
The results of our analyses were sensitive to alternative assumptions. The base case analyses assumed that pneumococcal and influenza vaccines would be given concomitantly and that the preventive effect of pneumococcal vaccination would be in addition to that of influenza vaccination. When the analyses considered that pneumococcal vaccine would be given by itself, CERs increased, but they could still be regarded as moderately cost-effective in all 5 countries.
The results were sensitive to assumptions on the incidence of invasive disease. The large differences in reported incidence among different countries (table 1) seem not to be related to real variations in the magnitude of disease occurrence but rather to differences in surveillance systems and case ascertainment (D. S. Fedson et al., unpublished observations). The large differences in the incidence of invasive disease that have been found between different regions within individual countries in single years strengthens this argument. Thus, the comparatively high incidence of invasive disease in Spain (table 1) may be a more realistic estimate of its true incidence in all 5 countries than the lower rates reported from the other 4 countries. The sensitivity analyses showed that the economic attractiveness of Downloaded from https://academic.oup.com/cid/article-abstract/31/2/444/295929 by guest on 03 January 2019 pneumococcal vaccination increases considerably when higher incidences are applied to each country.
The cost-effectiveness of vaccination to prevent invasive disease was also sensitive to assumptions on mortality rates. For Belgium, Scotland, and Spain, mortality data on pneumonia were applied as proxies for mortality data for invasive disease because the latter were not available. Because invasive disease is the most severe manifestation of pneumococcal pneumonia, the mortality rate of invasive disease was most likely underestimated in Belgium and Spain (table 1) . Population-based studies and case series from several other countries indicate that mortality rates for invasive disease among persons aged у65 years are usually 20%-40% [17] . The sensitivity analyses showed that for most countries, vaccination becomes economically more attractive when these mortality rates are applied.
The mutual application of presumed common incidences (50 cases per 100,000 elderly persons) and mortality rates (20%-40%) for invasive disease in the 2-way sensitivity analyses showed that CERs for pneumococcal vaccination would be approximately р12,000 ecu per QALY in all 5 countries. We believe that these findings provide a useful corrective for the otherwise disparate results obtained when the actual epidemiological data reported for each country were used in the base case analyses.
The results of our cost-effectiveness analyses for invasive disease in the 5 western European countries were different from the results for the United States, which showed that vaccinating all elderly persons was cost-saving under most assumptions [23] . Almost all of the epidemiological and economic variables used in the US study were more favorable toward vaccination than those applied in our base case analyses. The US analysis assumed a higher incidence of bacteremic disease, a higher mortality rate (29%), lower vaccine purchase and administration costs (together, 9.3 ecu), and higher hospitalization costs (6971 ecu per episode of hospitalization). In addition, the US study did not assume simultaneous administration of pneumococcal and influenza vaccines. However, the differences in cost-effectiveness estimates between the US and western European analyses cannot be ascribed wholly to the use of different values for these variables. When we applied the epidemiological and economic data used in the US study to our model, we obtained a CER of ∼1500 ecu per QALY. Part of this difference might be ascribed to the use of different values for other variables and/or the use of a different model. We used a cohort model (in contrast to the Markov model used in the US study). Nonetheless, like the investigators who conducted the US study, we believe that our cost-effectiveness estimates are conservative; both analyses covered only hospitalization for invasive disease and disregarded health improvements or cost saving stemming from vaccination that might reduce the need for outpatient care. Including these costs or the costs of hospitalization for nonbacteremic pneumococcal pneumonia would make pneumococcal vaccination more economically attractive.
Several constraints on the availability of data from the different countries may have affected our results. As in the US study [23] , we did not include the time lost for persons who were vaccinated. This variable should be captured by measuring the reduction in quality of life [36] , which (because of the few hours involved) would be negligible. In addition, we applied the same age-dependent quality-of-life weights for persons in all 5 European countries that were used in the US study. There is little reason to assume, however, that quality-of-life weights should differ appreciably between European countries and the United States; therefore, the impact of this assumption on our results is likely to have been small. Finally, as in the US study, our base case analyses excluded costs in life years gained because of vaccination. Whether to include these costs is a topic of considerable debate [25] ; their inclusion has a large negative effect on the cost-effectiveness of any lifesaving health care intervention.
In summary, we have shown that pneumococcal vaccination to prevent invasive pneumococcal disease is acceptably to moderately cost-effective in 5 western European countries. Moreover, when plausible assumptions on the incidence and mortality rate of invasive disease are applied to all 5 countries, CERs for pneumococcal vaccination are approximately р12,000 ecu per QALY. If vaccination is also clinically effective in preventing pneumococcal pneumonia, it is always highly cost-effective and usually cost-saving. Because of the similarity of the results in all 5 countries, pneumococcal vaccination is likely to be acceptably cost-effective in other western European countries as well. On the basis of our findings, we believe that public health authorities should consider policies for encouraging pneumococcal vaccination of all persons aged у65 years.
